ArticleDiscover oncology2026

Identification of SLIT3 mutation as a response biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.